Ron Bentsur bought $250K of Nuvectis Pharma (NVCT)

Executed Jun 30, disclosed Jul 1, 1 day later.

Value, as filed

$250K

12,500 sh × $20.00

Executed

Jun 30

the trade date, as filed

Disclosed

Jul 1

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

+22.3%

-0.7% from execution

Over the 21 trading sessions from the disclosed entry session (Jul 1), the stock returned +22.3% (delay-adjusted); from the execution session (Jun 30), -0.7%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

RB Ron Bentsur Chairman & CEO profile →

Ron Bentsur (Chairman & CEO) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Nuvectis Pharma, Inc. (NVCT). Across 1 priced purchase filing, the average 21-session return was -0.7% from execution and +22.3% from disclosure (delay-adjusted; derived). The largest single filing was $250K of NVCT (12,500 sh × $20.00, as filed), executed Jun 30.

The name

NVCT Nuvectis Pharma, Inc. NVCT · Healthcare · 7 filings in 24 months ticker →

Healthcare · Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of s…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→